Phase II trial to assess the combination of lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma [ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAIDA]

Trial Profile

Phase II trial to assess the combination of lenalidomide in patients with relapsed or refractory Hodgkin's lymphoma [ENSAYO FASE II PARA VALORAR LA COMBINACIÓN DE LENALIDOMIDA CON DOSIS METRONÓMICAS DE CICLOFOSFAMIDA EN PACIENTES CON LINFOMA DE HODGKIN CLÁSICO REFRACTARIO O EN RECAIDA]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Cyclophosphamide (Primary) ; Lenalidomide (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top